Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5857 Target Snapshot

Trace amine-associated receptor 1 · SINGLE PROTEIN · Homo sapiens

779Compounds
50Assays
18Approved Drugs
1,289.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Trace amine-associated receptor 1 shows late clinical disease relevance led by schizophrenia. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q96RJ0. Start with schizophrenia, then reuse UniProt Q96RJ0 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with schizophrenia, then reuse UniProt Q96RJ0 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
schizophrenia

Trace amine-associated receptor 1 shows late clinical disease relevance led by schizophrenia. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include ULOTARONT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Trace amine-associated receptor 1 as ChEMBL target CHEMBL5857, mapped to UniProt Q96RJ0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Trace amine-associated receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5857
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96RJ0
Trace amine-associated receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Trace amine-associated receptor 1 is the right protein anchor across sources, using UniProt Q96RJ0 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why schizophrenia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTrace amine-associated receptor 1
UniProt AccessionQ96RJ0
Component TypeProtein
Sequence Length339 aa

Trace amine-associated receptor 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Trace amine-associated receptor 1, mapped to UniProt Q96RJ0. Sequence length is 339 aa.

Mapped IDQ96RJ0
Review nameTrace amine-associated receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Trace amine-associated receptor 1 shows late clinical disease relevance led by schizophrenia. 4 more disease programs remain visible in the same review block.

Late clinical Phase III
schizophrenia
1 linked drug · 1 direct · 1 efficacy
Linked drugULOTARONT
Clinical signal Phase II
generalized anxiety disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugULOTARONT
Clinical signal Phase II
major depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugULOTARONT
Clinical signal Phase I
narcolepsy-cataplexy syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugULOTARONT
Clinical signal Phase I
Parkinson disease
1 linked drug · 1 direct · 1 efficacy
Linked drugULOTARONT
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include ULOTARONT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseschizophrenia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

18
Approved
5
Phase III
4
Phase II
Assay Mix

Activity Type Distribution

IC50458.0
KI50.0
EC50781.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4301324 8.93 EC50 1.17 Preclinical
CHEMBL2206400 8.7 Ki 2.0 Preclinical
CHEMBL2206385 8.7 Ki 2.0 Preclinical
CHEMBL5082760 8.46 EC50 3.5 Preclinical
CHEMBL2206890 8.4 Ki 4.0 Preclinical
CHEMBL2206377 8.4 Ki 4.0 Preclinical
CHEMBL2206376 8.4 Ki 4.0 Preclinical
CHEMBL2206890 8.34 EC50 4.6 Preclinical
CHEMBL2206381 8.3 Ki 5.0 Preclinical
CHEMBL2206375 8.22 Ki 6.0 Preclinical
Distribution

pChEMBL Value Distribution

353
5.0
260
5.5
132
6.0
91
6.5
58
7.0
36
7.5
12
8.0
3
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOLAZOLINE HYDROCHLORIDE
CHEMBL1689
Approved 1985
GUANABENZ
CHEMBL420
Approved 1982
TETRAHYDROZOLINE HYDROCHLORIDE
CHEMBL1200413
Approved 1979
NAPHAZOLINE HYDROCHLORIDE
CHEMBL1706
Approved 1971
DEXTROAMPHETAMINE
CHEMBL612
Approved 1955
Assay Landscape

Assay Landscape

50
Total Assays
617
Tested Compounds
2
Assay Types
Functional — 41 assays, 617 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 39 615 5.7
assay format 2 2 5.3
Binding — 9 assays, 70 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 1 6.8
cell-based format 3 67 6.9
assay format 1 2 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine